Dr. Jeffrey Campbell -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Jeffrey Campbell, a Oncology physician based in Pittsburgh, PA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Jeffrey Campbell has received $32,940.30 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Jeffrey Campbell
- Medical Specialty: Oncology
- Practice Location: Pittsburgh, PA, Pennsylvania
- NPI Number: 1821720629
- Transparency Score: 50/100
- Payment Records Span: 2025-03-08 to 2025-03-08
Payment Summary
Dr. Jeffrey Campbell has received a total of $32,940.30 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $32,940.30 per transaction.
- Total Payments Received: $32,940.30
- Number of Transactions: 1
- Average Payment: $32,940.30
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Oncology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Jeffrey Campbell's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Consulting Fees | $32,940.30 | Advisory board participation, clinical consulting, and expert opinion services |
The largest payment category for Dr. Jeffrey Campbell is Consulting Fees, accounting for 100% ($32,940.30) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Jeffrey Campbell. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| AbbVie Inc | $32,940.30 | 1 |
Dr. Jeffrey Campbell has a financial relationship with AbbVie Inc, receiving $32,940.30 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Jeffrey Campbell. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Wegovy -- Referenced in payment records from pharmaceutical companies to Dr. Jeffrey Campbell
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Jeffrey Campbell's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. Jeffrey Campbell, an Oncologist in Pittsburgh, PA, has a pharmaceutical payment profile characterized by a single, substantial payment. With a total of $32,940.30 from pharmaceutical companies, Dr. Campbell's payment volume is significantly higher than the average for oncologists, who typically receive payments in the range of a few thousand dollars annually, often spread across multiple interactions. The entirety of this payment comes from AbbVie Inc., a major biopharmaceutical company, for consulting services rendered on March 8, 2025. This singular, high-value consulting payment from one company warrants careful consideration. While consulting is a legitimate professional activity, a large sum from a single entity can raise questions about potential influence. Oncology is a field where pharmaceutical innovation is rapid, and oncologists often engage with drug manufacturers to stay abreast of new treatments and research. However, the concentration of this payment from AbbVie Inc. is notable. Patients should understand that these payments are intended to facilitate the exchange of information and expertise. Nevertheless, it is crucial for patients to maintain awareness that such financial relationships exist. The context of these payments is important: they can support valuable professional development and research, but they also necessitate transparency to ensure patient trust and to mitigate any perception of bias in treatment decisions. Patients should feel empowered to discuss any concerns about their doctor's financial relationships with them directly, seeking clarity on how these interactions inform their care.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Jeffrey Campbell is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When considering your doctor's relationship with pharmaceutical companies, it's important to approach the information with a balanced perspective. Payments can facilitate the sharing of vital information about new treatments and research, which can ultimately benefit patient care. However, transparency is key to maintaining trust. At your next appointment, consider asking your doctor about their professional relationships with drug manufacturers. You might inquire, 'Do you work with any pharmaceutical companies, and how does that inform your understanding of new treatments?' Red flags to watch for include a doctor who seems overly enthusiastic about a specific drug without a clear clinical rationale, or if they consistently prescribe medications from companies they have significant financial ties with, especially if there are equally effective, less expensive alternatives. Normal professional activity often involves smaller, recurring payments for speaking engagements, advisory boards, or meals, spread across various companies. A single, large payment, particularly for consulting, might warrant closer examination, though it doesn't automatically imply bias. Evaluate your doctor's prescribing patterns by looking at whether they consider a range of treatment options, discuss the pros and cons of different medications, and prioritize your individual needs and insurance coverage. Remember, the goal is to ensure your treatment plan is based on the best available evidence and your personal health circumstances.
Peer Comparison: How Dr. Jeffrey Campbell Compares to Other Oncology Physicians
Dr. Campbell's total payment of $32,940.30 from one interaction is considerably higher than the average for oncologists. While many oncologists receive payments for various activities like speaking, consulting, or research, the average annual total for the specialty typically falls within the range of $1,000 to $5,000, often distributed across several smaller payments from different companies. Dr. Campbell's profile, with one large payment, stands out significantly from this typical distribution.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Jeffrey Campbell in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| AbbVie Inc | $32,940.30 | consulting | Wegovy | 2025-03-08 | Not Assessed |
Frequently Asked Questions About Dr. Jeffrey Campbell's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. Jeffrey Campbell taking too much pharma money?
Dr. Campbell received a single payment of $32,940.30 for consulting from AbbVie Inc. This amount is substantially higher than the average annual payments received by oncologists, which typically range from $1,000 to $5,000 and are often distributed across multiple interactions. While this single large payment is notable and significantly exceeds the norm, it is important to consider the context. Consulting can be a legitimate professional activity. However, the concentration of such a large sum from one company may warrant closer attention from patients regarding potential influence on treatment recommendations.
What pharma companies pay Dr. Jeffrey Campbell?
Dr. Jeffrey Campbell received payments exclusively from AbbVie Inc. The total amount paid by AbbVie Inc. to Dr. Campbell is $32,940.30. This payment was for consulting services.
Should I switch doctors because of pharma payments?
Switching doctors solely based on pharmaceutical payments is a significant decision that should be based on a comprehensive evaluation of your care. While it's important to be aware of potential influences, a doctor's financial relationships don't automatically mean they are providing suboptimal care. Consider the nature and volume of payments. A single, large payment, like Dr. Campbell's, might prompt questions, but it's not an automatic reason to leave. If you have concerns about your doctor's prescribing habits, their communication about treatment options, or if you feel your trust has been eroded, then discussing these concerns or seeking a second opinion might be appropriate. Focus on whether your doctor is transparent, discusses all treatment options, and prioritizes your individual needs.
What kinds of payments does this doctor receive?
Dr. Campbell's payment profile consists of a single payment totaling $32,940.30, which was categorized as consulting. There are no recorded payments for speaking, meals, travel, research, or ownership interests from pharmaceutical companies in the provided data.
How do these payments compare to other Oncology?
Dr. Campbell's total payment of $32,940.30 from one interaction is considerably higher than the average for oncologists. While many oncologists receive payments for various activities like speaking, consulting, or research, the average annual total for the specialty typically falls within the range of $1,000 to $5,000, often distributed across several smaller payments from different companies. Dr. Campbell's profile, with one large payment, stands out significantly from this typical distribution.
Do pharma payments affect prescribing quality?
Research suggests that financial relationships between doctors and pharmaceutical companies can influence prescribing patterns, potentially leading to increased use of promoted drugs, even when alternatives exist. Studies have shown that doctors who receive payments may be more likely to prescribe brand-name medications. However, the extent of this influence varies, and many doctors maintain ethical practices. It's important to remember that payments can also support legitimate professional activities like research and education. The key is transparency and critical evaluation of treatment recommendations in light of these relationships.
How can I verify this payment data?
You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. This publicly accessible website allows you to search for physicians and teaching hospitals to view payments and other transfers of value they have received from pharmaceutical and medical device manufacturers. You can access the database by searching for 'CMS Open Payments' online and using the search tools to find Dr. Jeffrey Campbell by name or NPI number (1821720629).
Understanding This Doctor Payment Report
This transparency report for Dr. Jeffrey Campbell is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Oncology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Jeffrey Campbell's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Jeffrey Campbell and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Oncology Specialty Payment Data -- See payment patterns for all oncology physicians
- Pennsylvania Physician Payments -- Browse pharmaceutical payments to physicians in Pennsylvania
- Oncology Physicians in Pennsylvania -- Compare Dr. Jeffrey Campbell to peers in the same state and specialty
- AbbVie Inc Payment Profile -- View all payments made by Dr. Jeffrey Campbell's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Jeffrey Campbell's NPI (1821720629) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.